Clinical Trials Browser

Interventional × Melanoma × zanolimumab × Clear all

NCT01160445 2015-10-28

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

Phase 2 Terminated

9 enrolled 9 charts

DermatologicGenitourinary

Kidney Neoplasms, Melanoma